{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:21:10Z","timestamp":1791249670024,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.tmrv.2023.150747","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T11:53:00Z","timestamp":1686916380000},"page":"150747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Transmission of Variant Creutzfeldt-Jakob Disease Through Blood Transfusion and Plasma-Derived Products: A Narrative Review of Observed and Modeled Risks"],"prefix":"10.1016","volume":"37","author":[{"given":"Alexis","family":"Pozzo di Borgo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Rochette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaury","family":"Gaussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila F\uff0e","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2023.150747_bib0001","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/978-1-4614-0653-2_6","article-title":"Creutzfeldt-Jakob disease","volume":"724","author":"Sikorska","year":"2012","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.tmrv.2023.150747_bib0002","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","article-title":"Prions","volume":"95","author":"Prusiner","year":"1998","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.tmrv.2023.150747_bib0003","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra2119323","article-title":"Laboratory diagnosis of Creutzfeldt\u2013Jakob disease","volume":"386","author":"Zerr","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2023.150747_bib0004","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/39057","article-title":"Transmissions to mice indicate that \u2018new variant\u2019 CJD is caused by the BSE agent","volume":"389","author":"Bruce","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.tmrv.2023.150747_bib0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/38925","article-title":"The same prion strain causes vCJD and BSE","volume":"389","author":"Hill","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.tmrv.2023.150747_bib0006","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(19)30615-2","article-title":"Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation","volume":"20","author":"Uttley","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tmrv.2023.150747_bib0007","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ana.20708","article-title":"Risk factors for variant Creutzfeldt\u2013Jakob disease: a case\u2013control study","volume":"59","author":"Ward","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tmrv.2023.150747_bib0008","unstructured":"Creutzfeldt-Jakob Disease International Surveillance Network. vCJD cases worldwide. https:\/\/www.eurocjd.ed.ac.uk\/data_tables (accessed February 2, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0009","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0140-6736(96)91412-9","article-title":"A new variant of Creutzfeldt-Jakob disease in the UK","volume":"347","author":"Will","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2023.150747_bib0010","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/oxfordjournals.bmb.a072654","article-title":"Epidemiology and control of bovine spongiform encephalopathy (BSE)","volume":"49","author":"Bradley","year":"1993","journal-title":"Br Med Bull"},{"key":"10.1016\/j.tmrv.2023.150747_bib0011","unstructured":"Ministry of Food, Agriculture and Fisheries of Denmark - Danish Veterinary and Food Administration. The feed ban and the TSE regulation. https:\/\/www.foedevarestyrelsen.dk\/english\/Animal\/Feed\/Pages\/The_feed_ban_and_the_TSE_regulation.aspx (accessed February 2, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0012","unstructured":"Centers for Disease Control and Prevention. Bovine Spongiform Encephalopathy (BSE), or mad cow disease - feed bans. https:\/\/www.cdc.gov\/prions\/bse\/feed-ban.html (accessed February 2, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0013","series-title":"Management of health risks from environment and food - policy and politics of health risk management in five countries-asbestos and BSE","first-page":"221","article-title":"Chapter 8: BSE in the United Kingdom","author":"Webster","year":"2010"},{"key":"10.1016\/j.tmrv.2023.150747_bib0014","series-title":"Prions and diseases","first-page":"213","article-title":"Chapter 12: Risk of transmission of Creutzfeldt\u2013Jakob Disease by blood transfusion","author":"Peden","year":"2023"},{"key":"10.1016\/j.tmrv.2023.150747_bib0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJMc1610003","article-title":"Variant Creutzfeldt\u2013Jakob disease in a patient with heterozygosity at PRNP codon 129","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2023.150747_bib0016","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/0140-6736(91)93128-V","article-title":"Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease","volume":"337","author":"Collinge","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2023.150747_bib0017","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/pgmj.2004.029124","article-title":"Diabetes and ethnic minorities","volume":"81","author":"Oldroyd","year":"2005","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.tmrv.2023.150747_bib0018","doi-asserted-by":"crossref","first-page":"e15626","DOI":"10.1371\/journal.pone.0015626","article-title":"Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK","volume":"5","author":"Garske","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2023.150747_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-3-4","article-title":"Updated projections of future vCJD deaths in the UK","volume":"3","author":"Ghani","year":"2003","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.tmrv.2023.150747_bib0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.2008.07376.x","article-title":"An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products","volume":"144","author":"Turner","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2023.150747_bib0021","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1365-2141.2012.09201.x","article-title":"Dealing with the uncertain risk of variant Creutzfeldt-J akob disease transmission by coagulation replacement products","volume":"158","author":"Millar","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2023.150747_bib0022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.tracli.2007.04.008","article-title":"Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal","volume":"14","author":"Flan","year":"2007","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tmrv.2023.150747_bib0023","first-page":"50","article-title":"Variant Creutzfeldt-Jakob disease: an update","volume":"50","author":"Ironside","year":"2012","journal-title":"Folia Neuropathol"},{"key":"10.1016\/j.tmrv.2023.150747_bib0024","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/vox.13416","article-title":"Safety profile of plasma for fractionation donated in the United Kingdom, with respect to variant Creutzfeldt\u2013Jakob disease","volume":"118","author":"Thomas","year":"2023","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2023.150747_bib0025","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/vox.12631","article-title":"Creutzfeldt-Jakob disease and blood transfusion safety","volume":"113","author":"Seed","year":"2018","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2023.150747_bib0026","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(04)15486-X","article-title":"Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion","volume":"363","author":"Llewelyn","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2023.150747_bib0027","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(04)16811-6","article-title":"Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient","volume":"364","author":"Peden","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2023.150747_bib0028","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/S0140-6736(06)69835-8","article-title":"Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report","volume":"368","author":"Wroe","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2023.150747_bib0029","unstructured":"The National CJD Research & Surveillance Unit (NCJDRSU). The Transfusion Medicine Epidemiology Review (TMER). https:\/\/www.cjd.ed.ac.uk\/projects\/transfusion-medicine-epidemiology-review-tmer (accessed February 3, 2023)."},{"issue":"3","key":"10.1016\/j.tmrv.2023.150747_bib0030","article-title":"Fourth case of transfusion-associated variant-CJD infection","volume":"1","year":"2007","journal-title":"Health Protection Report"},{"key":"10.1016\/j.tmrv.2023.150747_bib0031","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2516.2009.02181.x","article-title":"Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia","volume":"16","author":"Peden","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.tmrv.2023.150747_bib0032","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/vox.12426","article-title":"Ten-year follow-up of two cohorts with an increased risk of variant CJD: donors to individuals who later developed variant CJD and other recipients of these at-risk donors","volume":"111","author":"Checchi","year":"2016","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2023.150747_bib0033","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2516.2011.02508.x","article-title":"The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products","volume":"17","author":"Zaman","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.tmrv.2023.150747_bib0034","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/vox.12358","article-title":"No evidence of asymptomatic variant CJD infection in immunodeficiency patients treated with UK-sourced immunoglobulin","volume":"110","author":"Helbert","year":"2016","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2023.150747_bib0035","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0268-960X(98)90007-8","article-title":"New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion","volume":"12","author":"Turner","year":"1998","journal-title":"Blood Rev"},{"key":"10.1016\/j.tmrv.2023.150747_bib0036","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1537-2995.1999.39111169.x","article-title":"Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans","volume":"39","author":"Brown","year":"1999","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0037","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/vox.12004","article-title":"Removal of TSE agent from plasma products manufactured in the United Kingdom","volume":"104","author":"Roberts","year":"2013","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2023.150747_bib0038","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/trf.12637","article-title":"Risk assessment for transmission of variant Creutzfeldt-Jakob disease by transfusion of red blood cells in the United States","volume":"54","author":"Yang","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0039","unstructured":"Medicines & Healthcare products Regulatory Agency. Use of UK plasma for the manufacture of immunoglobulins and vCJD risk - Critical Risk Assessment Report 2021. https:\/\/www.gov.uk\/government\/publications\/critical-risk-assessment-report-use-of-uk-plasma-for-the-manufacture-of-immunoglobulins-and-vcjd-risk (accessed February 3, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.transci.2008.05.006","article-title":"Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment","volume":"39","author":"Svae","year":"2008","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tmrv.2023.150747_bib0041","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/vox.13290","article-title":"Risk of variant Creutzfeldt\u2013Jakob disease transmission by blood transfusion in Australia","volume":"117","author":"McManus","year":"2022","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2023.150747_bib0042","unstructured":"Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9. Analyse du risque de transmission de la nouvelle variante de la maladie de Creutzfeldt-Jakob par le sang et ses d\u00e9riv\u00e9s 2000. https:\/\/archiveansm.integra.fr\/var\/ansm_site\/storage\/original\/application\/de3b1f29712c9a4c83db5844eac8d2fa.pdf (accessed February 3, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0043","unstructured":"Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9. Analysis of the risk of transmission of variant of Creutzfeldt-Jakob disease by health products and by tissues and fluids of human origin - Update of findings of ad hoc group report of December 2000. 2004. https:\/\/archiveansm.integra.fr\/var\/ansm_site\/storage\/original\/application\/2906328b3b0e08c665a7c7b0e5c42020.pdf (accessed February 3, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0044","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/j.1537-2995.2012.03637.x","article-title":"Cost-effectiveness of prion filtration of red blood cells to reduce the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease in the Republic of Ireland","volume":"52","author":"Teljeur","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0045","unstructured":"US Food and Drug Administration. Draft quantitative risk assessment of vCJD risk potentially associated with the use of human plasma-derived factor VIII manufactured under United States (US) license from plasma collected in the US 2006. https:\/\/www.fda.gov\/media\/73877\/download (accessed May 8, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0046","unstructured":"Department of Health & Social Care. Risk assessment of the transmission of vCJD by blood components - Technical report 2019. https:\/\/www.gov.uk\/government\/publications\/vcjd-transmission-by-blood-components-risk-assessment (accessed February 3, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0047","unstructured":"Advisory Committee on the Safety of Blood, Tissues and Organs. Importation of plasma and use of apheresis platelets as risk reduction measures for variant Creutzfeldt-Jakob Disease - Paediatric Components Working Group - Report 2019. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/829906\/SaBTO_PC_report.pdf (accessed February 3, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0048","first-page":"347","article-title":"Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey","author":"Gill","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.tmrv.2023.150747_bib0049","unstructured":"Serious Hazards of Transfusion (SHOT). Annual Shot Report 2021. https:\/\/www.shotuk.org\/wp-content\/uploads\/myimages\/SHOT-REPORT-2021-FINAL-bookmarked-V3-November.pdf (accessed March 22, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/tme.12840","article-title":"Importation of plasma and use of apheresis platelets as risk reduction measures for variant Creutzfeldt-Jakob disease: The SaBTO review","volume":"32","author":"Thomas","year":"2022","journal-title":"Transfus Med"},{"key":"10.1016\/j.tmrv.2023.150747_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eclinm.2019.10.014","article-title":"Is it time to rethink UK restrictions on blood donation?","volume":"15","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tmrv.2023.150747_bib0052","unstructured":"Irish Blood Transfusion Service. vCJD. https:\/\/www.giveblood.ie\/can-i-give-blood\/keeping-blood-safe\/vcjd\/ (accessed March 24, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0053","unstructured":"US Food and Drug Administration. Recommendations to Reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood components. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-possible-risk-transmission-creutzfeldt-jakob-disease-and-variant-creutzfeldt (accessed February 3, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0054","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/trf.13971","article-title":"Geographic exposure risk of variant Creutzfeldt-Jakob disease in US blood donors: a risk-ranking model to evaluate alternative donor-deferral policies","volume":"57","author":"Yang","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0055","unstructured":"Australian Government - Department of Health and Aged Care. TGA approval to change blood donation rules relating to vCJD deferral. https:\/\/www.tga.gov.au\/news\/news\/tga-approval-change-blood-donation-rules-relating-vcjd-deferral (accessed February 3, 2023)."},{"key":"10.1016\/j.tmrv.2023.150747_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(98)24035-9","article-title":"Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease","volume":"352","author":"Hilton","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2023.150747_bib0057","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1046\/j.0041-1132.2003.00586.x","article-title":"Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy","volume":"43","author":"Cervenakova","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0058","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1128\/JVI.06532-11","article-title":"Prionemia and leukocyte-platelet-associated infectivity in sheep transmissible spongiform encephalopathy models","volume":"86","author":"Lacroux","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.tmrv.2023.150747_bib0059","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009276","article-title":"Preclinical transmission of prions by blood transfusion is influenced by donor genotype and route of infection","volume":"17","author":"Salamat","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tmrv.2023.150747_bib0060","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(04)16812-8","article-title":"Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood","volume":"364","author":"Gregori","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2023.150747_bib0061","doi-asserted-by":"crossref","first-page":"e42019","DOI":"10.1371\/journal.pone.0042019","article-title":"Impact of leucocyte depletion and prion reduction filters on TSE blood borne transmission","volume":"7","author":"Lacroux","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2023.150747_bib0062","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1537-2995.2006.00865.x","article-title":"Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands","volume":"46","author":"Gregori","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0063","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(06)69897-8","article-title":"Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins","volume":"368","author":"Gregori","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2023.150747_bib0064","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/trf.13145","article-title":"A prion reduction filter does not completely remove endogenous prion infectivity from sheep blood","volume":"55","author":"McCutcheon","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0065","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/trf.12999","article-title":"Evaluation of the protection of primates transfused with variant Creutzfeldt-Jakob disease\u2013infected blood products filtered with prion removal devices: a 5-year update","volume":"55","author":"Lescoutra-Etchegaray","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0066","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/trf.12420","article-title":"Removal of exogenous prion infectivity in leukoreduced red blood cells unit by a specific filter designed for human transfusion","volume":"54","author":"Lescoutra-Etchegaray","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0067","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1537-2995.2009.02525.x","article-title":"Evaluation of removal of prion infectivity from red blood cells with prion reduction filters using a new rapid and highly sensitive cell culture\u2013based infectivity assay","volume":"50","author":"Sowemimo-Coker","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0068","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/trf.12369","article-title":"Assessment of prion reduction filters in decreasing infectivity of ultracentrifuged 263 K scrapie-infected brain homogenates in \u201cspiked\u201d human blood and red blood cells","volume":"54","author":"Cardone","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0069","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1423-0410.2007.01016.x","article-title":"A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity","volume":"94","author":"Poelsler","year":"2008","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2023.150747_bib0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0042-9007.2004.00379.x","article-title":"Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States","volume":"86","author":"Marshall","year":"2004","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2023.150747_bib0071","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/vox.12538","article-title":"Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV","volume":"112","author":"Custer","year":"2017","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2023.150747_bib0072","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/trf.16926","article-title":"Cost-effectiveness of pathogen reduction technology for plasma and platelets in Qu\u00e9bec: A focus on potential emerging pathogens","volume":"62","author":"Gr\u00e9goire","year":"2022","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0073","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1126\/science.1218167","article-title":"The risk of prion zoonoses","volume":"335","author":"Collinge","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.tmrv.2023.150747_bib0074","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1093\/brain\/awv235","article-title":"Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years","volume":"138","author":"Rudge","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.tmrv.2023.150747_bib0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(06)70413-6","article-title":"Predicting susceptibility and incubation time of human-to-human transmission of vCJD","volume":"5","author":"Bishop","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tmrv.2023.150747_bib0076","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/bmj.38804.511644.55","article-title":"Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study","volume":"332","author":"Ironside","year":"2006","journal-title":"BMJ"},{"issue":"26","key":"10.1016\/j.tmrv.2023.150747_bib0077","article-title":". Summary results of the third national survey of abnormal prion prevalence in archived appendix specimens","volume":"10","year":"2016","journal-title":"Health Protect Rep"},{"key":"10.1016\/j.tmrv.2023.150747_bib0078","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41582-021-00488-7","article-title":"The importance of ongoing international surveillance for Creutzfeldt\u2013Jakob disease","volume":"17","author":"Watson","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.tmrv.2023.150747_bib0079","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41467-017-01347-0","article-title":"Experimental transfusion of variant CJD-infected blood reveals previously uncharacterised prion disorder in mice and macaque","volume":"8","author":"Comoy","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.tmrv.2023.150747_bib0080","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1111\/trf.14145","article-title":"Creutzfeldt-Jakob disease lookback study: 21 years of surveillance for transfusion transmission risk","volume":"57","author":"Crowder","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150747_bib0081","unstructured":"European Centre for Disease Prevention and Control. EU case definition. https:\/\/www.ecdc.europa.eu\/en\/infectious-diseases-public-health\/variant-creutzfeldt-jakob-disease\/eu-case-definition (accessed March 7, 2023)."}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796323000378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796323000378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:21:25Z","timestamp":1760138485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796323000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0887796323000378"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2023.150747","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transmission of Variant Creutzfeldt-Jakob Disease Through Blood Transfusion and Plasma-Derived Products: A Narrative Review of Observed and Modeled Risks","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2023.150747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"150747"}}